Leerink Partners analyst Lili (Aurélie) Nsongo has maintained their bullish stance on ARCT stock, giving a Buy rating yesterday.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Lili (Aurélie) Nsongo’s rating is based on several key observations from the interim data of Arcturus Therapeutics’ Phase 2 studies for ARCT-810. The data indicated that ammonia levels remained within the normal range for most patients, which is a positive sign for the treatment’s safety profile. Although there were some instances of transient asymptomatic transaminase elevation, these were manageable and did not raise significant safety concerns.
Furthermore, the studies showed a significant decrease in glutamine levels for a majority of patients, particularly those with higher baseline levels. This suggests that the treatment may have a beneficial effect on managing glutamine levels, which is a critical factor in the condition being studied. Despite some challenges in interpreting efficacy due to dosing variability and small sample sizes, the overall data supports a positive outlook for ARCT-810, justifying the Buy rating.
In another report released yesterday, BTIG also maintained a Buy rating on the stock with a $48.00 price target.